Community Health Media
By Community Health Media
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Community Health Media
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 71
Description
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.
We specialize in:
• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts
| Episode | Date |
|---|---|
|
Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh
|
Sep 01, 2026 |
|
This Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran
|
Aug 13, 2026 |
|
This Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi
|
Aug 13, 2026 |
|
This Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo
|
Aug 13, 2026 |
|
This Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri
|
Aug 13, 2026 |
|
Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC
|
Jul 21, 2026 |
|
Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC
|
Jul 07, 2026 |
|
Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09
|
Jun 26, 2026 |
|
Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC
|
Jun 26, 2026 |
|
MATTERHORN Roundtable: Perioperative FLOT & Immunotherapy Updates in Gastric Cancer
|
Jun 25, 2026 |
|
EMERALD-3 Roundtable: Hepatocellular Carcinoma Trial Breakdown & Insights
|
Jun 25, 2026 |
|
Dr. Ursa Brown Glaberman & Dr. Karthik Giridhar- Managing Capiva-sertib & the AKT Path-way in 2L mBC
|
Jun 25, 2026 |
|
Dr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer
|
Jun 25, 2026 |
|
Dr. Jason Mouabbi, Dr. Fenting Yan, & Dr. Paolo Tarantino - First-Line T-DXd in HER2+ mBC
|
Jun 25, 2026 |
|
Dr. Abi Siva & Dr. Carey Anders - DESTINY-Breast05, DESTINY- Breast11 and T-DXd Integration
|
Jun 25, 2026 |
|
Dr. Megan Kruse, Dr. Ryan Rader, & Dr. Praveen Vikas - DB11 & DB05 Change HER2+ Care
|
Jun 25, 2026 |
|
Dr. Megan Kruse, Dr. William Gradishar, & Dr. Ajaz Khan - Integrating T-DXd Across HER2+ Care
|
Jun 25, 2026 |
|
Dr. Mark Pegram & Dr. Seth Wander - Endocrine Resistance & ESR1 Mutations
|
Jun 25, 2026 |
|
Dr. Jason Mouabbi, Dr. Alison Conlin & Dr. Reva Basho - Frontline TNBC and ADC Advances
|
Jun 25, 2026 |
|
Dr. Gregory Vidal, Dr. Pooja Advani, & Dr. Tari King - T-DXd in Early HER2+ Breast Cancer
|
Jun 25, 2026 |
|
Dr. Hope Rugo, Dr. Sarah Hurvitz, & Dr. Jennifer Tseng - T-DXd: New Curative Approvals & HER2+ Landscape
|
Jun 25, 2026 |
|
Dr. Nusayba Bagegni & Dr. Philip Lammers - Targeting & Sequencing Endocrine Pathways After CDK4/6i
|
Jun 25, 2026 |
|
Dr. Sangeetha Reddy & Dr. Ahmed Elkhanany - First-Line ADCs IN Metastatic Triple-Negative Breast Cancer
|
Jun 25, 2026 |
|
Dr. Mabel Mardones & Dr. Joyce O'Shaughnessy - T-DXd in Early HER2+ Breast Cancer
|
Jun 25, 2026 |
|
Dr. Joyce O'Shaughnessy, Dr. Anthony Lucci, & Dr. Mothaffar Rimawi - DB11 & DB05 Change HER2+ Care
|
Jun 25, 2026 |
|
Dr. Marcela Mazo Canola, Dr. Akshjot Puri, & Dr. Giancarlo Moscol - AKT-Pathway Sequencing in ER+ mBC
|
Jun 25, 2026 |
|
Dr. Caitlin Taylor & Dr. Andrew Davis - Can Camizestrant Change HR+ Breast Cancer Care?
|
Jun 25, 2026 |
|
Dr. Komal Jhaveri, Dr. Shanu Modi, & Dr. Sarah Tolaney - Early Stage HER2+ Breast Cancer: DB11 & DB05
|
Jun 25, 2026 |
|
Dr. Megan Kruse & Dr. Lukas Delasos - ADC Integration & Toxicity in Breast and Thoracic Oncology
|
May 15, 2026 |
|
Dr. Rao & Dr. Nasrazadani – The Second-Line Landscape for HR+/HER2- mBC: The Role of Capivasertib
|
May 14, 2026 |
|
Dr. Hope Rugo & Dr. Rebecca Shatsky - Dato-DXd & First-Line ADC Strategies in Metastatic TNBC
|
May 08, 2026 |
|
Dr. Hope Rugo & Dr. Rebecca Shatsky - Earlier ESR1 Detection & Oral SERDs in Metastatic Breast Cancer
|
May 08, 2026 |
|
Dr. Neil Iyengar & Dr. Ticiana Leal - ADC Integration in Breast & Lung Cancer: The Role of Dato-DXd
|
May 08, 2026 |
|
Dr. Iyengar, Dr. Bhave & Dr. Mahtani – ESR1 Monitoring & Camizestrant in Metastatic Breast Cancer
|
May 08, 2026 |
|
Dr. Megan Kruse & Dr. Carol Tweed – ESR1 Mutation Monitoring & Oral SERDs in Metastatic Breast Cancer
|
May 08, 2026 |
|
Dr. Jason Mouabbi & Dr. Ahmed Elkhanany - SERENA-6, ESR1 Mutations & Molecular Progression
|
May 08, 2026 |
|
Dr. Rebecca Shatsky & Dr. Reva Basho - Sequencing PI3K/AKT Therapies in Metastatic Breast Cancer
|
May 08, 2026 |
|
Drs. Neil Iyengar, Manali Bhave & Reshma Mahtani - Navigating AKT Inhibition Efficacy & Tolerability
|
May 08, 2026 |
|
Dr. Erica Mayer & Dr. Seth Wander - Biomarker Testing & Precision Targeting in the PI3K Pathway
|
May 08, 2026 |
|
Dr. Seth Wander & Dr. Erica Mayer - SERENA-6 and Camizestrant in Breast Cancer
|
May 08, 2026 |
|
Drs. Alvarez, Dr. Mazo-Canola & Dr. Sandoval-Leon - The Future of Breast Cancer Treatment & Precision Oncology
|
May 08, 2026 |
|
Dr. Jason Mouabbi & Dr. Eric Singhi - ADCs in Breast & Lung Cancer
|
May 07, 2026 |
|
Dr. Sigrun Hallmeyer & Dr. William Gradishar - SERENA-6 & Early Endocrine Resistance
|
May 07, 2026 |
|
Dr. VK Gadi & Dr. Tarah Ballinger - DB09, PATINA, DB05 & DB11 in HER2+ Breast Cancer
|
May 06, 2026 |
|
Dr. Ruta Rao & Dr. VK Gadi - Can T-DXd Change Early HER2+ Breast Cancer Forever?
|
Jan 08, 2026 |
|
Dr. Irene Kang & Dr. Aditya Bardia - First-Line HER2+ Metastatic Breast Cancer: DESTINY-Breast09 & the Future of Care
|
Jan 06, 2026 |
|
Dr. Neil Iyengar & Dr. Komal Jhaveri - Early-Stage HER2+ Breast Cancer: DESTINY-Breast11, DESTINY-Breast05 & What Comes Next
|
Jan 06, 2026 |
|
Dr. Gregory Vidal & Dr. Nusayba Bagegni - Is HER2+ Metastatic Breast Cancer Curable? DESTINY-Breast09, Patina & What Comes Next
|
Jan 06, 2026 |
|
Dr. Alison Conlin & Dr. Heather McArthur - DB-11 & DB-05: Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy
|
Jan 06, 2026 |
|
Drs. Bill Gradishar, Tarah Ballinger, & Megan Kruse - HER2+ Metastatic Breast Cancer: Cleopatra, DESTINY-Breast09 & What Comes Next
|
Jan 06, 2026 |
|
Dr. Mark Pegram & Dr. Carol Tweed - Is Cleopatra Finally Over? New First-Line Strategies in HER2+ Metastatic Breast Cancer
|
Jan 06, 2026 |
|
Drs. Neil Iyengar, Komal Jhaveri, & Igor Makhlin - HER2+ Metastatic Breast Cancer: Is T-DXd + Pertuzumab the New First-Line Standard?
|
Jan 06, 2026 |
|
Dr. Neil Iyengar & Dr. Martin Dietrich - DESTINY-Breast09: Has HER2+ First-Line Treatment Officially Changed?
|
Jan 06, 2026 |
|
Drs. Amy Krie, Mabel Mardones, & Anne O'Dea - HER2+ Metastatic Breast Cancer: Is DB09 Leading Towards A New First-Line Standard Of Care?
|
Jan 06, 2026 |
|
Dr. Mark Pegram & Dr. Fengting Yan - Destiny-Breast09: Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer?
|
Jan 02, 2026 |
|
Dr. Bill Gradishar & Dr. Tiffany Traina - Is First-Line mTNBC Changing? Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained
|
Jan 02, 2026 |
|
Drs. Mouabbi, O’Shaughnessy & Rimawi - 40-Month PFS? Rethinking First-Line Metastatic HER2+ Therapy with T-DXd
|
Dec 30, 2025 |
|
ESMO 2025 Roundtable: Redefining HER2, ADCs & the Future of Breast Cancer Care
|
Dec 24, 2025 |
|
Dr. Neil Iyengar & Dr. Erika Hamilton - First-Line TNBC: How TRO-Breast02 & ASCENT-03 Change the Game
|
Dec 11, 2025 |
|
Dr. Gregory Vidal and Dr. Erika Hamilton - TDXd in Early Breast Cancer: What DB-05 & DB-11 Mean for Patients
|
Dec 03, 2025 |
|
Dr. Mark Pegram & Dr. Ana Garrido-Castro – Breakthrough Data in Metastatic TNBC
|
Dec 01, 2025 |
|
Dr. Jason Mouabbi, Dr. Irene Kang, and Dr. Ruemu Birhiray - HER2+ Early Breast Cancer: Beyond pCR and Toward Brain Protection
|
Nov 20, 2025 |
|
Dr. Neil Iyengar & Dr. Mark Robson - PARP Inhibitors in Early Breast Cancer: Who and When to Treat
|
Nov 17, 2025 |
|
Dr. Mark Pegram & Dr. Neil Iyengar - Beyond CLEOPATRA: T-DXd’s Rise in HER2+ and HER2-Low Breast Cancer
|
Nov 10, 2025 |
|
Dr. VK Gadi & Dr. Anne O'Dea - Advances in HER2 Positive Breast Cancer Treatment
|
Sep 05, 2025 |
|
Dr. VK Gadi & Dr. Jason Mouabbi - HER2 Positive & HER2 Low Updates and Therapies
|
Sep 05, 2025 |
|
Dr. Jason Mouabbi & Dr. Mothaffar Rimawi - DB09 & The Future of HER2+Care
|
Aug 21, 2025 |
|
Dr. Jason Mouabbi & Dr. Michelina Cairo - Talking DB04 and DB06
|
Aug 21, 2025 |
|
Dr. VK Gadi & Dr. Fengting Yan - Navigating HER2 Low and Ultra Low Disease
|
Jul 31, 2025 |
|
Dr. Aditya Bardia and Dr. Reena Callahan - Redefining HER2 Classifications and Treatments
|
Jul 08, 2025 |
|
Dr. Jason Mouabbi & Dr. Paolo Tarantino - T-Dxd, HER2 Low & The Future of Breast Cancer Treatment
|
Jun 10, 2025 |